CEND-1
Phase 2Small molecule
Qilu Pharmaceutical Co., Ltd.CEND-1 is one of 85 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
84
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Gemzar
GGynecologic Oncology Group
Preclinical
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
CEND-1
Qilu Pharmaceutical Co., Ltd.Phase 2
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
LDE225
NovartisPreclinical
Sulfonylureas
Eli LillyPreclinical
Thiazolidinediones
SanofiPreclinical
Alpha-Glucosidase Inhibitors
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Ductal Adenocarcinoma2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CEND-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details